Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above Fifty Day Moving Average – Here’s Why

Akari Therapeutics PLC (NASDAQ:AKTX)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $9.50 and traded as high as $11.00. Akari Therapeutics shares last traded at $10.12, with a volume of 16,369 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AKTX shares. Maxim Group upgraded Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Monday, July 20th. Wall Street Zen raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Finally, Weiss Ratings upgraded shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Akari Therapeutics Stock Performance

The company’s 50-day simple moving average is $9.43 and its 200-day simple moving average is $9.04.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression.

Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation.